Clinical Study Of Schizophrenia in Both Men and Women

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: October 30, 2003
Last updated: October 4, 2010
Last verified: October 2010
The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.

Condition Intervention Phase
Drug: lamotrigine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multi-Center, Double Blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine Versus Placebo As Add-On Therapy In Schizophrenia

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change from baseline in the total score of the 7 items of the Positive and Negative Symptom Scale (PANSS) positive symptom subscale for lamotrigine vs. placebo at Week 12. [ Time Frame: 12 Weeks ]

Secondary Outcome Measures:
  • Change from baseline in the PANSS total score at Week 12; Change from baseline in the Scale for the Assessment of Negative Symptoms (SANS) at Week 12; Change from baseline in the Clinical Global Impression-Severity of Illness (CGI-S) score at Week 12. [ Time Frame: 12 Weeks ]

Estimated Enrollment: 176
Study Start Date: August 2003
Study Completion Date: January 2005
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception.
  • Diagnosis of Schizophrenia
  • Patients must be taking clozapine monotherapy or other atypical antipsychotic at least 3 months prior to this study.

Exclusion criteria:

  • Patients who are currently taking or have taken antidepressant medication in the last month prior.
  • Patients who are or have been suicidal or homicidal in the last 6 months.
  • Patients with a history of autistic disorder or another pervasive developmental disorder
  • Patients whose condition is due to the direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00071747

  Hide Study Locations
United States, Arkansas
GSK Investigational Site
Little Rock, Arkansas, United States, 72201
United States, California
GSK Investigational Site
Garden Grove, California, United States, 92845
GSK Investigational Site
La Mesa, California, United States, 91942
GSK Investigational Site
National City, California, United States, 91950
GSK Investigational Site
Oceanside, California, United States, 92056
GSK Investigational Site
Rosemead, California, United States, 91770
GSK Investigational Site
San Diego, California, United States, 92126
United States, Connecticut
GSK Investigational Site
Hartford, Connecticut, United States, 06106
United States, Florida
GSK Investigational Site
Maitland, Florida, United States, 32751
GSK Investigational Site
North Miami, Florida, United States, 33161
United States, Illinois
GSK Investigational Site
Granite City, Illinois, United States, 62040
United States, Maryland
GSK Investigational Site
Glen Burnie, Maryland, United States, 21061
GSK Investigational Site
Rockville, Maryland, United States, 20852
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02114
United States, Nevada
GSK Investigational Site
Reno, Nevada, United States, 89512
United States, New Jersey
GSK Investigational Site
Clementon, New Jersey, United States, 08021
GSK Investigational Site
Kenilworth, New Jersey, United States, 07033
United States, New York
GSK Investigational Site
Orangeburg, New York, United States, 10962
GSK Investigational Site
Rochester, New York, United States, 14620
United States, North Carolina
GSK Investigational Site
Butner, North Carolina, United States, 27509
GSK Investigational Site
Charlotte, North Carolina, United States, 28211
GSK Investigational Site
Raleigh, North Carolina, United States, 27603
GSK Investigational Site
Raleigh, North Carolina, United States, 27609
United States, Ohio
GSK Investigational Site
Beachwood, Ohio, United States, 44122
GSK Investigational Site
Cleveland, Ohio, United States, 44106
GSK Investigational Site
Lyndhurst, Ohio, United States, 44124
United States, Pennsylvania
GSK Investigational Site
Norristown, Pennsylvania, United States, 19401
United States, Texas
GSK Investigational Site
Austin, Texas, United States, 78756
GSK Investigational Site
Bellaire, Texas, United States, 77401
GSK Investigational Site
DeSoto, Texas, United States, 75115
United States, Utah
GSK Investigational Site
Midvale, Utah, United States, 84047
United States, Wisconsin
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

Responsible Party: Study Director, GSK Identifier: NCT00071747     History of Changes
Other Study ID Numbers: SCA30926 
Study First Received: October 30, 2003
Last Updated: October 4, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers processed this record on August 24, 2016